Search for content, post, videos

AstraZeneca to acquire CinCor Pharma

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, a US-based clinical-stage biopharmaceutical company, focused on developing novel treatments for resistant and uncontrolled hypertension as well as chronic kidney disease. The acquisition will bolster AstraZeneca’s car
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.